Occuity Named Finalist in UKBAA Angel Investment Awards 2026

We are delighted to announce that Occuity has been named a finalist in the Hard Tech Investment of the Year category at the UK Business Angels Association (UKBAA) Angel Investment Awards 2026.

The award recognises outstanding companies and investors operating in research-intensive and capital-intensive sectors that are shaping the future economy through innovation, technology and commercial impact. Sponsored by Mathys & Squire, the category celebrates achievements across areas such as health and life sciences, engineering and advanced manufacturing.

The winners will be announced at the UKBAA Angel Investment Awards ceremony, taking place at The Brewery in London on 9 July 2026.

Recognition for innovation and investor support

Being shortlisted is a significant achievement and reflects not only the progress Occuity has made in developing breakthrough healthcare technologies, but also the continued support of the angel investors who have backed our vision.

Since its inception, Occuity has been focused on transforming healthcare through innovative, non-contact optical technologies. From the commercial launch of the PM1 Pachymeter to the continued development of the AX1 Axiometer and our wider Oculomics platform, the company has remained committed to delivering technologies that have the potential to improve patient outcomes while making healthcare more accessible.

This award shortlisting is recognition of the amazing support Occuity has received from our investors as the Hard Tech Investment of the Year category specifically recognises the partnership between ambitious founders and the investors who help bring complex, high-impact technologies to market. As a business developing novel medical technologies, we understand first-hand the importance of patient capital, long-term commitment and strategic support from the investment community.

Celebrating the early-stage investment ecosystem

The UKBAA Angel Investment Awards celebrate the success, determination and impact of the UK's angel and early-stage investment community. The awards recognise the founders, angel investors, crowdfunding platforms and venture capital firms that are helping innovative businesses grow and scale.

Over the years, Occuity has benefited from the support of a passionate and engaged investor base that shares our ambition to transform healthcare through innovation. This recognition is therefore a reflection of the wider community that has helped support our journey.

Looking ahead

As we continue to advance our portfolio of ophthalmic and Oculomics technologies, we remain focused on delivering meaningful innovation, building long-term value and creating technologies capable of making a real difference to patients around the world.

Thank you to everyone who has supported Occuity on this journey.